Cite
MLA Citation
Daniel Glazar et al.. “COMP-13. EARLY TUMOR VOLUME EVOLUTION ADAPTIVELY PREDICTS PATIENT-SPECIFIC RESPONSE AND PROGRESSION RISK TO RADIOTHERAPY, PEMBROLIZUMAB, AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA IN A PHASE I TRIAL.” Neuro-oncology, vol. 21, n.d., pp. vi63–vi64. http://access.bl.uk/ark:/81055/vdc_100101668632.0x00003b